Stephen A Harrison Selected Research

Edema (Dropsy)

10/2021	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
1/2020	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
11/2006	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen A Harrison Research Topics

Disease

97	Non-alcoholic Fatty Liver Disease 04/2024 - 01/2002
92	Fibrosis (Cirrhosis) 05/2024 - 01/2003
31	Liver Cirrhosis (Hepatic Cirrhosis) 05/2024 - 01/2016
29	Alcoholic Fatty Liver 12/2023 - 02/2006
26	Inflammation (Inflammations) 12/2023 - 01/2003
21	Insulin Resistance 12/2021 - 01/2002
20	Liver Diseases (Liver Disease) 03/2024 - 01/2004
19	Fatty Liver 05/2024 - 01/2003
12	Type 2 Diabetes Mellitus (MODY) 03/2024 - 01/2002
12	Weight Loss (Weight Reduction) 03/2024 - 04/2003
12	Chronic Hepatitis C 08/2013 - 06/2005
11	Body Weight (Weight, Body) 03/2024 - 02/2006
9	Obesity 03/2024 - 01/2002
9	Hepatocellular Carcinoma (Hepatoma) 01/2024 - 02/2003
7	Infections 01/2020 - 10/2005
5	Nausea 01/2024 - 11/2019
5	Pruritus (Itching) 01/2023 - 01/2020
4	Diarrhea 01/2024 - 10/2021
4	Disease Progression 07/2023 - 12/2019
4	Sclerosing Cholangitis 11/2022 - 01/2019
4	Anemia 10/2021 - 11/2010
4	Weight Gain 10/2021 - 10/2007
3	Hemorrhage 01/2024 - 01/2023
3	Hepatic Encephalopathy 01/2024 - 01/2023
3	Ascites 01/2024 - 01/2023
3	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 10/2023 - 01/2018
3	Portal Hypertension 12/2021 - 01/2020
3	Edema (Dropsy) 10/2021 - 11/2006
3	Fatigue 11/2020 - 11/2006
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2015 - 04/2006
3	Hepatitis C 03/2013 - 06/2008
3	Glucose Intolerance 10/2009 - 11/2006
2	Cardiovascular Diseases (Cardiovascular Disease) 03/2024 - 01/2016
2	Overweight 03/2024 - 01/2009
2	Cholestasis 10/2023 - 01/2022
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2023 - 03/2015
2	Esophageal and Gastric Varices (Esophageal Varices) 01/2023 - 01/2020
2	Varicose Veins (Varicose Vein) 01/2023 - 01/2020
2	Neoplasms (Cancer) 01/2021 - 12/2012
2	Cicatrix (Scar) 01/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 12/2023 - 03/2006
13	Ribavirin (Virazole)FDA LinkGeneric 08/2013 - 06/2006
12	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2024 - 03/2006
12	Glucose (Dextrose)FDA LinkGeneric 03/2024 - 01/2003
12	Protons (Proton)IBA 11/2023 - 11/2018
12	Transaminases (Aminotransferases)IBA 11/2023 - 08/2004
12	EnzymesIBA 01/2023 - 01/2003
11	Alanine Transaminase (SGPT)IBA 04/2023 - 03/2006
10	Insulin (Novolin)FDA Link 12/2023 - 01/2002
9	nasIBA 12/2023 - 01/2018
9	aldaferminIBA 09/2023 - 01/2018
8	LipidsIBA 11/2023 - 07/2013
8	Pioglitazone (Actos)FDA Link 01/2023 - 02/2006
8	InterferonsIBA 08/2013 - 10/2005
7	resmetiromIBA 05/2024 - 11/2019
7	Complement C3 (C3 Complement)IBA 08/2023 - 01/2019
5	semaglutideIBA 03/2024 - 10/2020
5	selonsertibIBA 01/2023 - 11/2019
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 06/2008
5	Alkaline PhosphataseIBA 01/2022 - 08/2006
5	CollagenIBA 01/2022 - 10/2018
5	Antiviral Agents (Antivirals)IBA 01/2019 - 06/2005
5	Vitamin E FDA LinkGeneric 05/2016 - 11/2003
4	fibroblast growth factor 21IBA 05/2024 - 12/2019
4	Hormones (Hormone)IBA 09/2023 - 01/2019
4	PegbelferminIBA 04/2023 - 12/2019
4	Collagen Type III (Type III Collagen)IBA 04/2023 - 01/2020
4	Bile Acids and Salts (Bile Acids)IBA 01/2023 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2008
4	AdiponectinIBA 10/2015 - 01/2009
4	CytokinesIBA 10/2015 - 01/2003
4	LDL Lipoproteins (beta Lipoproteins)IBA 03/2013 - 02/2006
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 03/2024 - 02/2024
3	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 11/2022 - 01/2021
3	simtuzumabIBA 01/2022 - 10/2018
3	Keratin-18 (Keratin 18)IBA 12/2021 - 01/2011
3	oxidized low density lipoproteinIBA 01/2021 - 09/2010
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2015 - 08/2008
3	2,4-thiazolidinedione (thiazolidinedione)IBA 02/2010 - 11/2006
2	Liraglutide FDA Link 03/2024 - 03/2024
2	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 01/2024 - 01/2021
2	obeticholic acidIBA 11/2023 - 01/2022
2	seladelparIBA 10/2023 - 01/2022
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2023 - 01/2016
2	cyclo(Arg-Pro) (CI 4)IBA 08/2023 - 01/2021
2	4-(3-chlorophenylsulfanyl)piperidineIBA 01/2023 - 12/2021
2	belapectinIBA 01/2023 - 01/2020
2	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2023 - 01/2020
2	LDL CholesterolIBA 01/2023 - 01/2021
2	BerberineIBA 11/2022 - 01/2021
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 02/2006
2	BilirubinIBA 12/2021 - 05/2015
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 06/2021 - 01/2020

Therapy/Procedure

44	Therapeutics 03/2024 - 11/2002
14	Liver Transplantation 01/2024 - 11/2005
6	Drug Therapy (Chemotherapy) 01/2023 - 11/2008
4	Bariatric Surgery 01/2018 - 11/2007
3	Glycemic Control 01/2021 - 11/2006
3	Subcutaneous Injections 01/2021 - 10/2018
3	Diet Therapy (Therapy, Diet) 09/2012 - 04/2003